A Multi-center, Open Label Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness.
Phase of Trial: Phase III
Latest Information Update: 15 Jun 2010
At a glance
- Drugs Darexaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 15 Jun 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 15 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Apr 2010 New trial record